With the ability to accurately detect extraskeletal disease, PET/CT and whole-body MRI can change treatment plans for high-risk breast and prostate cancer patients, according to a study published in the December issue of the Journal of Nuclear Medicine. {read more here}

The U.S. Centers for Medicare and Medicaid Services (CMS) has reaffirmed its decision not to reimburse for sodium fluoride (NaF) PET scans to detect bone metastases. {read more here}

FDG-PET/CT’s aptitude for finding distant metastases in patients with stage III invasive ductal carcinoma has prompted researchers to suggest that the National Comprehensive Cancer Network (NCCN) add histology to its guidelines for determining the best method of staging. {read more here}

Images of the brain using FDG-PET can accurately detect Alzheimer’s disease in patients presenting with primary progressive aphasia or corticobasal syndrome as focal onset dementias, according to a study published in The Journal of Nuclear Medicine. {read more here}